•Meta analysis using the most serious outcome reported shows 66% [52‑76%] and 86% [75‑92%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis and restriction to peer-reviewed studies or Randomized Controlled Trials.
•Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 30 studies show statistically significant improvements in isolation.
•Results are very robust — in worst case exclusion sensitivity analysis 53 of 64 studies must be excluded to avoid finding statistically significant efficacy.
•While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 25% of ivermectin studies show zero events in the treatment arm.
•Multiple treatments are typically used in combination, and other treatments could be more effective, including monoclonal antibodies which may be available in countries not recommending ivermectin (sotrovimab, casirivimab/imdevimab, and bamlanivimab/etesevimab).
•Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used, including treatments, as supported by Pfizer [Pfizer, TrialSiteNews]. Denying the efficacy of treatments increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage.
READ THE FULL REPORT HERE (it is lengthy and contains extremely detailed data):